Svjetlana Lozo, MD
Urogynecology and Reconstructive Pelvic Surgery · New York, NYNPI 1326277435
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,586 of the $2,049 with a category attached, or 77.4%. 10 manufacturers reported payments, led by Coloplast at 31.4% of the total. 2025 is the largest year on record at $782, 4.2 times the $186 reported in 2019. That places this record below the midpoint for urogynecology and reconstructive pelvic surgery clinicians in NY, where the typical reported total is $2,552.
Across 38 payments — averaging $53.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Coloplast$644
- Medtronic$610
- Sumitomo Pharma America, Inc.$354
- Boston Scientific$242
- Applied Medical Resources Corporation$88
- Intuitive Surgical$32
- plus $78 from 4 others
Across 10 payments — averaging $3859.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ironwood Pharmaceuticals, Inc$39K
What the payments were for
- Travel & lodging$46323%
- Food & beverage$1,58677%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Coloplast | 6 | $644 |
| Medtronic(2 entities) | 7 | $610 |
| Sumitomo Pharma America, Inc. | 15 | $354 |
| Boston Scientific | 4 | $242 |
| Applied Medical Resources Corporation | 1 | $88 |
| Intuitive Surgical | 1 | $32 |
| AbbVie | 1 | $20 |
| Dentsply IH AB | 1 | $20 |
| Agile Therapeutics, Inc. | 1 | $19 |
| Bayer | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ALTIS$571
- ALTAVIVA$426
- GENERAL FEMALE SUI$127
How this compares
$2,049 in reported general payments places this provider in the 40th percentile of 90 urogynecology and reconstructive pelvic surgery providers in New York.
See all urogynecology and reconstructive pelvic surgery providers in New York →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 234 | $164,331 |
| Estradiol | 674 | $41,963 |
| MyrbetriqMirabegron | 21 | $17,518 |
| Fosfomycin Tromethamine | 20 | $7,340 |
| Clobetasol Propionate | 75 | $3,456 |
| YuvafemEstradiol | 14 | $3,208 |
| Trospium Chloride ErTrospium Chloride | 34 | $3,175 |
| Methenamine Hippurate | 65 | $2,829 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 73 | $1,090 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 43 | $856 |
| Cefpodoxime Proxetil | 23 | $821 |
| Ibuprofen | 61 | $230 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 37 | $64 |
| Ciprofloxacin Hcl | 18 | $57 |
| Oxycodone Hcl | 40 | $52 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $354 | $164,331234 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 90 urogynecology and reconstructive pelvic surgery providers in New York.
Other urogynecology and reconstructive pelvic surgery in New York
- Ido SirotaNew York$12K
- Christina EscobarNew York$12K
- Kimberly FerranteNew York$11K
- Alan GarelyNew York$7K
- Larissa RodriguezNew York$5K
- Melissa LaudanoNew York$4K
- Feven GetanehNew York$4K
- Chandhana PakaNew York$4K
- Lisa DabneyNew York$2K
- Matan MekaytenNew York$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.